Ingrezza's Potential To Dominate The Huntington's Chorea Market: A Boost For Neurocrine Investors
Seeking Alpha · 1d ago
Neurocrine Biosciences Earnings Preview
Benzinga · 1d ago
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
Benzinga · 1d ago
Neurocrine rises as Morgan Stanley upgrades citing label expansion for lead asset
Seeking Alpha · 2d ago
Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130
Benzinga · 2d ago
--Morgan Stanley Upgrades Neurocrine Biosciences to Overweight From Equal Weight, Adjusts Price Target to $130 From $120
--Morgan Stanley Upgrades Neurocrine Biosciences to Overweight From Equal Weight, Adjusts Price Target to $130 From $120
MT Newswires · 2d ago
Insider Sell: Neurocrine Biosciences
Insider Sell: Neurocrine Biosciences
MT Newswires · 2d ago
Mizuho Securities Sticks to Their Hold Rating for Neurocrine (NBIX)
TipRanks · 6d ago
Neurocrine Biosciences: Stencil In These Important Dates
Seeking Alpha · 01/25 17:55
Neurocrine Biosciences: Scope For Valuation Upside With Ingrezza Numbers
Seeking Alpha · 01/24 09:04
Stocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A Wildcards
Seeking Alpha · 01/21 15:00
Volume Breakout Report Update: Buy Eton Pharmaceuticals
Seeking Alpha · 01/17 03:41
Voyager: Recent Neurocrine Deal Signals More Upside
Seeking Alpha · 01/14 09:19
Needham Sticks to Its Hold Rating for Neurocrine (NBIX)
TipRanks · 01/12 11:05
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Neurocrine (NBIX)
TipRanks · 01/12 11:01
Robert W. Baird Sticks to Its Buy Rating for Neurocrine (NBIX)
TipRanks · 01/12 05:25
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
Investor Place · 01/09 16:24
Voyager jumps 29% on licensing deal with Neurocrine
Seeking Alpha · 01/09 14:27
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
Benzinga · 01/09 14:15
Voyager, Neurocrine ink gene-therapy deal
MarketWatch · 01/09 13:15
Webull provides a variety of real-time NBIX stock news. You can receive the latest news about Neurocrine Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.